Loading
A phase 2 trial of Sonrotoclax and Zanubrutinib in waldenström macroglobulinaemia, run by BeOne Medicines, active and no longer recruiting.
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia is a phase 2 interventional study registered as NCT05952037 by BeOne Medicines, with 114 participants enrolled, started 2023-10-23 and due to reach its primary completion in 2026-09-22. Interventions recorded: Sonrotoclax and Zanubrutinib.
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene).